DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Treatment with Anakinra improves disposition index but not insulin sensitivity in nondiabetic subjects with the metabolic syndrome: a randomized, double-blind, placebo-controlled study.

Author(s): van Asseldonk EJ, Stienstra R, Koenen TB, Joosten LA, Netea MG, Tack CJ

Affiliation(s): Department of Internal Medicine, Radboud University Nijmegen Medical Centre, 6500 HB Nijmegen, The Netherlands. e.vanasseldonk@aig.umcn.nl

Publication date & source: 2011-07, J Clin Endocrinol Metab., 96(7):2119-26. Epub 2011 Apr 20.

Publication type: Randomized Controlled Trial; Research Support, Non-U.S. Gov't

CONTEXT: Obesity induces low-grade inflammation that may promote the development of insulin resistance. IL-1 is one of the key inflammatory factors. OBJECTIVE: The objective of the study was to demonstrate improvement of insulin sensitivity by blocking IL-1. DESIGN: This was a randomized, double-blind, crossover study. SETTING: The study was based on ambulatory care. PARTICIPANTS: Participants included nondiabetic, obese subjects with the metabolic syndrome. INTERVENTION: Intervention included 150 mg anakinra sc once daily or matching placebo for 4 wk. MAIN OUTCOME MEASURE: Insulin sensitivity as measured by euglycemic hyperinsulinemic clamp. RESULTS: A total of 13 of 19 subjects completed the study. Although anakinra treatment resulted in a significantly lower level of inflammation illustrated by a reduction in circulating C-reactive protein concentrations and leukocyte numbers, insulin sensitivity was not significantly different after anakinra treatment (2.8 x 10(-2) +/- 0.5 x 10(-2)) compared with placebo treatment (2.4 x 10(-2) +/- 0.3 x 10(-2) mumol/kg(-1) . min(-1) . pmol(-1), P = 0.15). Adipose tissue examination, performed to analyze local effects of IL-1 receptor antagonist, showed an increased influx of macrophages after treatment with anakinra most likely due to an injection site reaction caused by the vehicle (0.28 +/- 0.05 vs. 0.11 +/- 0.01 macrophages per adipocyte, P = 0.005). The differences in individual subject insulin sensitivity after anakinra as compared with placebo between subjects were negatively correlated with macrophage infiltration into the adipose tissue (r(2) = 0.46, P = 0.01). The disposition index increased significantly after anakinra treatment (P = 0.04), reflecting an improvement in beta-cell function. CONCLUSIONS: Our results suggest that anakinra does not improve insulin sensitivity in obese, insulin-resistant, nondiabetic subjects.

Page last updated: 2011-12-09

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2014